In this episode of Connecting ALS, Dave R. Zook, JD, an advisor with expertise in federal regulatory policy, speaks to the process of making drug coverage decisions for newly approved therapies.
Jeremy Holden
Advertisement
Communications Director, The ALS Association
Articles by Jeremy Holden
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
2
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
3
Therapeutic Promise and Mechanism of DYNE-101 to Treat Myotonic Dystrophy: Doug Kerr, MD, PhD
4
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
5
